Knight Therapeutics (KHTRF) Projected to Post Earnings on Thursday

Knight Therapeutics (OTCMKTS:KHTRF) will likely be releasing its results before the market opens on Thursday, November 5th. Analysts expect Knight Therapeutics to post earnings of $0.0098 per share and revenue of $90.74 million for the quarter.

Knight Therapeutics Stock Performance

OTCMKTS:KHTRF opened at $8.13 on Wednesday. The stock has a 50-day moving average price of $7.47 and a 200 day moving average price of $6.15. Knight Therapeutics has a 12-month low of $4.11 and a 12-month high of $8.31.

Analysts Set New Price Targets

Separately, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Knight Therapeutics in a report on Friday, August 7th. One research analyst has rated the stock with a Buy rating. According to data from MarketBeat.com, the stock has a consensus rating of “Buy”.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a Canadian specialty pharmaceutical company focused on acquiring, licensing, commercializing and, in some cases, developing innovative prescription medicines. The company seeks products that address unmet medical needs, with an emphasis on pharmaceuticals and therapies that can be introduced through regulatory and commercial expertise rather than broad internal research operations.

Knight markets and supports a portfolio of specialty medicines through direct commercial activities and partnerships.